Skip to Content Skip to Search

Research and development

Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients

We deliver our long-term priorities of Innovation, Performance and Trust through each of our three businesses which discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our approach to Pharmaceutical Research and Development (R&D) focuses on science related to the immune system, and the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. It will help us to accelerate the pace at which we develop and deliver transformational medicines, prioritising those molecules with a higher probability of success and terminating less promising programmes. It also enables us to increase our focus on specialty medicines in areas such as oncology.

In our Vaccines business, we balance our focus on a robust pipeline with the active life-cycle management of our existing vaccines, seeking to protect more people through expanding indications and delivering our vaccines to new geographies. Our Innovation ambition is to lead the industry by disrupting the discovery, development and manufacturing of vaccines. We will focus on accelerating key assets in our pipeline and looking at innovative technologies so that we can unlock potential in emerging fields. Using our industry-leading science, we will accelerate the delivery of our most promising assets to serve the greatest unmet medical need. We want to change the world with our science.

Our Consumer Healthcare R&D organisation develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health. In the future, we will separate this business in a joint venture with Pfizer. 

Key facts about R&D at GSK

  • 12,000+

    Over 12,000 people working across our three global businesses

  • £4.6bn

    Our adjusted R&D investment in 2020

  • 57

    Our pipeline comprises 57 vaccines and medicines in development at FY 2020